Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: bromocriptine mesylate

« Back to Dashboard

Summary for Generic Name: bromocriptine mesylate

Drug Master File Entries: see list9
Suppliers: see list2
Therapeutic Class:Antiparkinson Agents
Hormonal Agents, Suppressant (Pituitary)

Pharmacology for Ingredient: bromocriptine mesylate

Drug ClassErgot Derivative

Clinical Trials for: bromocriptine mesylate

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects
Status: Recruiting Condition: Type 2 Diabetes

Effect of Cycloset on Glycemic Control When Added to GLP-1 Analogue Therapy
Status: Recruiting Condition: Type 2 Diabetes

Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg
Status: Completed Condition: Healthy

Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets
Status: Completed Condition: Healthy

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes Mellitus

Vaginal Bromocriptine for Treatment of Adenomyosis
Status: Active, not recruiting Condition: Adenomyosis

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
Status: Recruiting Condition: Parkinson's Disease

Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy
Status: Recruiting Condition: Peripartum Cardiomyopathy

Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study
Status: Not yet recruiting Condition: PCOS; Insulin Resistance

QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
Status: Completed Condition: Diabetes Mellitus, Type 2

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
bromocriptine mesylate
TABLET;ORAL020866May 5, 2009RXYes8,431,155<disabled>Y<disabled>
Zydus Pharms Usa Inc
bromocriptine mesylate
CAPSULE;ORAL078899Jul 30, 2008RXNo<disabled><disabled>
bromocriptine mesylate
TABLET;ORAL020866May 5, 2009RXYes7,888,310<disabled><disabled>
bromocriptine mesylate
TABLET;ORAL020866May 5, 2009RXYes8,613,947<disabled>Y<disabled>
bromocriptine mesylate
TABLET;ORAL020866May 5, 2009RXYes8,137,994<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn